Drug profile · INN
icatibant
CIPLA ICATIBANT
icatibant (CIPLA ICATIBANT) is a bradykinin b2 receptor antagonist. Associated with Cipla Australia Pty Ltd.
EMA: approved TGA: approved Blood and blood forming organs (B06) B06AC02
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — icatibant
- Class
- Blood and blood forming organs (B06)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
icatibant (CIPLA ICATIBANT) is a bradykinin b2 receptor antagonist. Associated with Cipla Australia Pty Ltd.
Key facts
INN icatibant
Brand CIPLA ICATIBANT
Mechanism Bradykinin B2 receptor antagonist
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AC02
Originator Cipla Australia Pty Ltd
Mechanism of action
Bradykinin B2 receptor antagonist
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is icatibant?
icatibant (CIPLA ICATIBANT) is a bradykinin b2 receptor antagonist. Associated with Cipla Australia Pty Ltd.
What is the brand name for icatibant?
CIPLA ICATIBANT is a marketed brand name for icatibant. Check FDA Drugs@FDA for the current US label holder and prescribing information.